NDAINTRACAMERALIMPLANT
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
4
Data completeness
4/8 — Partial
IDOSE TR (travoprost intracameral) by Glaukos. Approved for prostaglandin analog [epc]. First approved in 2023.
Drug data last refreshed Yesterday
Mechanism of Action
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Started Feb 2026
510 enrolled
Glaucoma
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
Started Jan 2026
20 enrolled
Open Angle GlaucomaPigmentary GlaucomaPseudoexfoliation Glaucoma
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Started Dec 2025
30 enrolled
Open Angle Glaucoma (OAG)Ocular Hypertension (OH)
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Started Jun 2025
610 enrolled
Glaucoma
Worked on IDOSE TR at Glaukos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.